INTRODUCTION
The p53 protein is a potent tumour suppressor that converts stress signals into cellular responses via activation or repression of many genes. 1 Mutations in the TP53 genes have been reported in more than 50% of all types of cancers.
2 p53, known as a 'guardian of genome', responses to various forms of cytotoxic stress by preventing the proliferation of genetically damaged cells through the control of their cell cycle and/or apoptosis. p53 executes stress-response programmes through regulation of expression of its target genes, including p21, GADD45α (cell cycle arrest), 3, 4 Puma, 5 Bax, 6 Noxa, 7 DR5, p53AIP, PIG3, APAF1 (apoptosis), BTG2, and PaI1(senescence). 4 In addition to protein-coding genes, p53 also controls a number of micro-RNA and long non-coding genes. [8] [9] [10] In unstressed cells p53 is a short-lived protein, which is rapidly degraded by ubiquitin-dependent mechanism in proteasomes. 11 Upon genotoxic stress, p53 becomes stabilized via multiple post-translational modificaitions, including phosphorylation, acetylation, methylation and so on. 12 Importantly, these genotoxic-induced post-translational modificaitions also downregulate the proteolytic activity of proteasomes 13, 14 thus providing further stabilization of p53 on the protein level.
Importantly, most of the lysine-specific post-translational modificaitions that control activity and stability of p53 are carried out by histone-modifying enzymes. 12, 15 For example, acetylation by histone acetyltransferase (HAT) p300/CBP renders p53 not only more stable, but also more transcriptionally active. [16] [17] [18] Methylation by lysine methyltransferase (KMT) Set7/9 augments the activity of p53 by promoting its acetylation via sequestering deacetylase (HDAC) Sirt1. 19, 20 Huang et al. 21 described another KMT, Smyd2, which acted, in contrast to Set7/9, as repressor of p53 activity. Additionally, Set8 and G9a were also shown to inhibit p53 under non-stressed conditions. 22, 23 G9a (EHMT2), a SET-domain histone methyltransferase protein, heterodimerises with G9a-like protein (GLP) via its carboxyl terminal SET domain to exert the full spectrum of its substrate methylation specificity. 24, 25 Both proteins (independently and in the complex) catalyse mono-and dimethylation of lysine 9 and lysine 27 of histone H3 (H3K9 and H3K27, respectively) [26] [27] [28] and histone H1 isotype 4 (H1.4). 29, 30 In addition, G9a was reported to mono-methylate lysine 56 of histone H3 (H3K56) during G1 phase to regulate DNA replication. 31 Furthermore, G9a and GLP methylate a number of non-histone substrates, among them CEBP β, HDAC1, DNMT1, KLF12, 32 and p53 (K373). 23 The current consensus on the role of G9a in regulation of transcription is that it works as a transcriptional co-repressor. However, recent studies have challenged this view by showing that G9a also positively regulates gene expression of hormone receptors by recruiting GRIP1, CARM1, and p300 factors and thus acts as a co-activator. 33 Interestingly, the underlying mechanism of G9a function as a positive regulator is methylation-independent, because UNC0646 (G9a-specific methyltransferase inhibitor) can not abolish this feature. 33, 34 Here, we report an unexpected finding that human and mouse G9a orthologues regulate p53 in opposite ways. Specifically, the human version of G9a (hG9a) augmented the activity of p53 towards its target genes irrespective of the methylation, while the mouse one (mG9a) blunted p53-dependent transcription in the methylation-specific manner. Futhermore, we uncovered the molecular mechanism of G9a-mediated activation of p53, which relied on the recruitment by G9a of at least one coactivator HAT, CBP. The latter event resulted in increased histone acetylation and activation of the p53 target genes, including Puma. RESULTS hG9a induces p53 transcriptional activity Several HMTs have already been shown to methylate p53 in the regulatory domain and control its activity (Figure 1a) . 12 Since the carboxyl terminus of p53 is rich in lysines that could be potentially methylated, we decided to screen for additional HMTs that methylate p53 and affect its activity. A panel of recombinant GST-SET domains from 20 various HMTs (a gift from Dr Binda, Newcastle, UK) was analysed for methylation of p53 in vitro (the full list of HMTs tested is available upon request). Under these experimental conditions we could not detect any new HMTs, besides the already known ones (for example, Set7/9 and Smyd2) that robustly methylated p53 (Supplementary Figure S1) . Surprisingly, in contrast to previously published data 23 the G9a SET recombinant protein gave no methylation signal (Supplementary Figure S1 , upper panel). We then hypothesized that G9a may affect p53 activity in vivo. Thus, we examined hG9 and several other HMTs that were suspected to regulate p53 independently of its methylation (that is, Smyd3, a close relative of p53-specific HMT, Smyd2, and SetD2, which was shown previously to interact with p53 35 ) for their ability to control transactivation by p53. H1299 (p53 − / − ) human lung carcinoma cells transfected with p53 and HTM-coding plasmids were tested in luciferase assay for the ability of HMTs to control the activation of p53-dependent Puma-luciferase reporter (Figure 1b ). Smyd2 and Set7/9 were used as negative and positive controls, respectively. Surprisingly, opposite to our expectations, expression of hG9a further augmented 1.8-fold p53-dependent activation of the PUMA promoter compared to p53 alone (Figure 1b) . On the contrary, the reporter activity was reduced 1.5-fold in the presence of ) that shows p53 response to different HMTs (upper). The transfection efficiency was confirmed using western blot (Lower). Data shown in the figure are from three independent experiments. *Po0.05, **Po0.005. (c) Schematic representation of the domain structure of hG9a (S), hG9a (L), and mG9a, showing the transcription activation domain (TAD), ankyrin repeats (ANK), and a methyltransferase domain, which consists of pre-SET, SET, and post-SET. (d) Luciferase activity (in relative units) of Bax, Puma, and p21 reporters transfected into H1299 cells (upper). The transfection efficiency was confirmed using western blot (Lower). Data shown are from three independent experiments. *Po0.05, **Po0.005. (e) Luciferase activity (in relative units) of Puma reporter transfected into H1299 (p53 − / − ) cells (upper). Light bars denote no p53, grey bars denote human p53 (hp53), and black bars denote mouse p53 (mp53). The transfection efficiency was confirmed using western blot (Lower). Data shown are from three independent experiments. *Po0.05, **Po0.005. (f) Western blot results on the levels of Puma and p21 proteins in H1299 transfected with the indicated plasmids and treated with 1 μM of Doxorubicin for 24 h (left). Quantification of the intensity of endogenous p21 and Puma bands was performed using Image J software (NIH, Bethesda, MD, USA) and normalized to the signal of β-actin (right).
Smyd2, Smyd3, and SetD2. Expectedly, p53 alone activated transcription of the luciferase reporter 15-fold over the vector (pCDNA3) alone and Set7/9 displayed a modest but reproducible increase of p53-depedent activation of Puma. 36 The augmentation of p53 reporter activity by G9a was not due to overexpression of p53 since all the transfected samples contained comparable amounts of p53 as judged by western (Figure 1b , middle panel).
Following this unexpected result we next compared side by side the effect of hG9a isoforms and its mouse orthologue (Figure 1c ) on transcription of three bona fide p53 target genes: Bax, Puma, and p21 (Figure 1d ). The human G9a gene has two splice variants: hG9a long and hG9a short (Figure 1c) , which are also known as isoform-a and b. Isoform-a is a long isoform of G9a (hG9a(L)) composed of 1210 amino acids. This isoform encompasses two open reading frames: NG36 (amino acids 1-209) and G9a (amino acids 210-1210). Isoform-b is a short isoform of G9a dubbed as hG9a(S) and lacks the amino terminal part of isoform-a. 25, 37 The mouse G9a (mG9a) contains 1229 amino acids, and its composition is closer to isoform-a of human G9a than isoform-b (Figure 1c) . Following co-transfection of H1299 cells with p53 alone or in the presence of hG9a or mG9a with three different reporters (Bax-luc, Puma-luc, and p21-luc) the luciferase activity of each reporter was measured (Figure 1d , upper panel). Expression of p53 and G9a proteins was monitored by western blotting (Figure 1d , bottom panel). Results of luciferase assay showed that p53-dependent activation of the reporters was affected differently by human and mouse G9a (Figure 1d ). Specifically, expression of hG9a(S) augmented the p53 activity on Bax, Puma, and p21 promoters, while mG9a suppressed the activity of all these reporters. Similar results were also obtained for mouse E14 fibroblasts cells (Supplementary Figure S2) and HCT116 (p53 +/+ and p53
) colorectal cancer cells, demonstrating that hG9a co-activates transcription in the p53-dependent manner (Supplementary Figure S3) . Furthermore, the regulation of p53 by hG9a was promoter-dependent, giving maximum increase for the Puma reporter (approximately twofold over p53 alone) and modest 1.2-fold activation for Bax and p21 (Figure 1d ). This result indicates that hG9a acts on p53 in the gene-specific manner.
In addition, we extended our observations on activating propensity of G9a to the mouse p53 (mTp53) protein (Figure 1e ). When hG9a was co-expressed with mTp53 the activity of PUMA-Luc increased 1.5 fold over mTp53 alone. On the contrary, forced expression of mG9a repressed transactivation of both human and mouse p53. Note that neither hG9a nor mG9a themselves were able to augment the reporter activity suggesting that these were p53-dependent events.
To corroborate these results, we performed western blotting on similarly transfected H1299 cells before and after genotoxic stress induced by doxorubicin, which is a potent activator of p53 (Figure 1e ). We found that expression levels of endogenous Puma were elevated in p53-and hG9a-expressing samples after doxorubicin (Figure 1f, upper panel) . However, expression of p21 was only slightly augmented (1.3-fold) by hG9a and p53 (Figures 1e and f, lower panel) . Importantly, ectopically expressed mG9a in the presence of p53 repressed both p21 and Puma reporters (Figure 1f, upper panel) . Collectively, these results suggest that hG9a, unlike its mouse counterpart, activated p53-dependent transcription, resulting in the augmented Puma expression after doxorubicin treatment.
Human G9a splice variants and its homolog, GLP, enhance Puma expression Since the hG9a gene product is present in two isoforms (G9a(S) and G9a(L)) we sought to determine whether the long isoform of hG9a and its homolog, GLP, 38 also participated in p53 regulation. To this end, H460 cells, which harbour wild type p53, were transfected with the indicated plasmids and treated or not treated with doxorubicin to elicit p53 response. Expression levels of endogenous p21 and Puma genes were analyzed by quantitative reverse transcription PCR (qRT-PCR) (Figure 2a ). The transfection efficiency was monitored by western blotting using specific antibodies ( Figure 2b ). Both isoforms of hG9a and GLP facilitated p53-dependent transcription of Puma. However, in respect to p21, G9a proteins behaved differently, that is, hG9a(S) and GLP further stimulated p53 activation, whereas hG9a(L) failed to do this ( Figure 2a , upper panel). Taken together, these results suggest that hG9a stimulated transcription induced by endogenous p53. Similar outcome was observed when the expression of p21 and Puma was analyzed in H460 cells by luciferase assay (Supplementary Figure S3) .
So far, our results demonstrated that overexpression of hG9a stimulated p53-transcriptional activity in several human cancer cell lines. To validate our observations in a more physiological setting we examined the effect of shRNA against hG9a (shG9a) on p53-dependent transcription (Figure 2c ). H1299 cells were transfected with control or hG9a-specific shRNA along with p53 and control vectors in the presence or absence of doxorubicin. These cells were analysed for p21 and Puma expression by qRT − PCR (Figure 2d ). Attenuation of hG9a expression by shRNA was concomitant with a decrease in p53-dependent Puma expression ( Figure 2d ). In contrast, we did not observe any significant effect of shRNA-G9a on expression of the p21 gene. These data suggest that G9a specifically cooperates with p53 to regulate Puma expression in response to genotoxic stress. hG9a affects p53 activity by the methylation-independent mechanism Next, we wanted to elucidate whether the effect of hG9a on p53 was methylation-dependent since the previously published work argued that G9a inhibited transcriptional activity p53 via its di-methylation on lysine K373. 23 Therefore, we compared the effects of transfected human and mouse G9a on the ability of wild-type p53 and its methylation-deficient mutant p53 (K373R) to activate the PUMA-luciferase reporter ( Figure 3a) . Notably, the results showed that hG9a augmented the activity not only of wildtype p53 but also its unmethylatable mutant (K373R). In contrast, the mG9a-imposed repression was alleviated when the nonmethylatable mutant of p53 (K373R) was used ( Figure 3a , upper panel). This effect was not due to the attenuated level of p53 expression, because western blotting showed comparable amounts of p53 in each case ( Figure 3a , bottom panel). We also assessed the importance of G9a-dependent methylation for regulation of p53-dependent transcription using a specific inhibitor, BIX-01294 28 ( Figure 3b ). To this end, HCT116 p53-positive cells transfected with the Puma-luciferase reporter and either hG9a or mG9a were treated or not treated with BIX-01294 before measuring luciferase activity. The results shown in Figure 3b clearly demonstrated that inhibition of hG9a KMT activity did not have any effect on its ability to activate p53-dependent transcription. On the contrary, treatment of mG9a-expressing cells with BIX-01294 removed the repression of p53, suggesting that KMTase activity of mG9a was instrumental for repression of p53. Importantly, BIX-01294 did not affect transcription of the Puma-luciferase reporter in the absence of p53 (Figure 3b ). Further, both wild-type and the catalytically inactive hG9a (delta-SET) transfected into H1299 cells were able to co-activate the PUMA reporter by p53 (data not shown). Collectively, these results strongly suggest that hG9a facilitates the activity of p53 in the methylation-independent manner, whereas mG9a blunts the activity of p53 via methylation on K373 as previously reported. ) cells expressing control pLKO or shG9a#pooled constructs. Both Puma and p21 expression were quantified and normalised using GAPDH (housekeeping gene). Results are the mean of three independent experiments. *P o 0.05, **Po0.005, ***Po0.001, ****Po0.0001. hG9a cooperates with CBP to promote p53 activity To further uncover the molecular mechanism by which hG9a enhances the activity of p53 we assessed the effect of hG9a on p53 binding to the target gene promoters by chromatin immunoprecipitation (ChIP) assay (Figures 4a and b) . To this end, H460 cells were transfected with either hG9a(S) or hG9a(L) constructs and treated or not treated with doxorubicin to elicit p53 response. ChIP assay was then performed using p53-specific antibody. As shown in Figure 4b , overexpression of both hG9a isoforms augmented p53 binding to the promoter of Puma even in the absence of DNA damage (Figure 4b, lower panel) . However, this effect was not pronounced in the case of p53 binding to the p21 promoter (Figure 4b, upper panel) . Upon doxorubicin treatment, ectopic hG9a(S) and, to a lesser extent, hG9a(L) further increased p53 binding to both p21 and Puma promoters. Similar pattern of p53 binding was also observed in H1299 cells (Supplementary Figure S4) . Importantly, mG9a repressed p53 binding to Puma, but had no effect on p53 binding to the promoter of p21 (Supplementary Figure S4) . Thus, our ChIP results suggest that hG9a, but not the mG9a, enhances p53 binding to PUMA promoter in both H460 and H1299 cells.
It is well established that p53 regulates transcription of its target genes predominantly via recruitment of specific coactivators. 39 One of the critical coactivators for p53 is histone acetyltransferase (HAT) p300/CBP. 16 Moreover, studies from Stallcup's group 33, 40 suggest that G9a controls transcription of a subset of Glucocorticoid receptor-dependent genes by recruiting p300, a close homologue of CBP. Having considered these facts, we hypothesized that hG9a facilitates p53-dependent recruitment of CBP to the PUMA promoter. To test this hypothesis we firstly determined whether p53, hG9a, and CBP physically interacted in H1299 cells. H1299 cells co-transfected with p53, Flag-hG9a(S), and CBP expression vectors were subjected to co-immunoprecipitation with Flag-antibody followed by immunoblotting with respective antibodies (Figure 4c ). Immunoprecipitates obtained with Flag-specific antibody but not with control IgG antibody contained Flag-G9a, p53, and CBP proteins (Figure 4c ). This result confirmed the existence of physical interaction between p53, G9a, and CBP. Because G9a was previously reported to localize both to the nucleus and cytoplasm, 37 we wanted to determine in which cellular compartment potential p53-hG9a-CBP interactions took place. As can be judged from Figure 4d , ectopic p53 and FlaghG9a co-localised to the nucleus, although a fraction of hG9a was also present in the cytoplasm. Similarly, Flag-G9a and CBP were also detected in the nucleus, suggesting that the interaction between all three proteins likely takes place in the nucleus and thus may have functional effect on transcription.
Next, we questioned whether the presence of hG9a facilitated the recruitment of CBP to the PUMA promoter in a p53-dependent manner. To address this question we performed ChIP assay with anti-CBP serum using HCT116 cells with endogenously expressed p53 and overexpressed hG9a and CBP. Since p53 is known to bind CBP 41 we also used HCT116 (p53
) cells to assess the recruitment dependency on p53 (Figure 4e ). We found that the recruitment of CBP to the PUMA promoter was p53-dependent. Furthermore, forced expression of hG9a significantly augmented the amount of CBP associated with chromatin as judged by PCR with PUMA-specific primers (Figure 4e) .
Functional recruitment of CBP to gene promoters is manifested in increased acetylation of histone H4 (H4ac). 42 Therefore, we examined levels of H4ac on the Puma promoter as a result of the p53-hG9a-CBP interaction (Figure 4f ). To address this question ChIP assay was performed using H460 (p53 +/+ ) cells transfected with either empty vector or hG9a(S) expression plasmid. To induce DNA damage cells were treated with doxorubicin. Results of the experiment revealed that upon DNA damage the level of histone H4 acetylation in the promoter region of Puma increased upon the presence of hG9a(S) (Figure 4f ), suggesting that hG9a-facilitated recruitment of CBP to the PUMA promoter was functional.
Subsequently, we investigated whether the hG9a-CBP interaction affected p53-dependent transcription (Figure 4g ). HCT116 cells (p53 + and p53 − ) were transfected individually with plasmids expressing hG9a, CBP, or their combination followed by luciferase assay using the PUMA-luciferase reporter (Figure 4g ). Our results suggested that both hG9a and CBP co-activated transcription of the p53-dependent reporter synergistically.
Lastly, we sought to examine whether the endogenously expressed CBP could affect the propensity of hG9a to augment p53-dependent transcription. Both types of HCT116 cells (p53 + and p53 − ) were transfected with shRNA against CBP or control plasmid pLKO (Figure 4h , lower panel) in the presence or absence of ectopic Flag-hG9a. Activation of PUMA-luc decreased twofold upon downregulation of CBP expression even when hG9a was overexpressed (Figure 4h ). These results indicate that hG9a cannot compensate for CBP deficiency to activate PUMA-luc, hence suggesting that CBP is upstream of hG9a in the process of p53 activation.
Expression of hG9a augments p53-dependent cell death To evaluate the physiological significance of hG9a-dependent effect on p53-dependent activation of Puma we performed the clonogenic assay using H460 p53-positive cells ectopically expressing either hG9a or mG9a with and without doxorubicin treatment (Figure 5a) . Importantly, expression of hG9a in H460 cells even without DNA damage resulted in a reduction of the number of colonies, which was further substantiated by genotoxic stress. In striking contrast to hG9a, forced expression of mG9a slightly increased the number of colonies after doxorubicin, arguing that mG9a inhibited the activity of p53.
Next, we conducted fluorescence-activated cell sorting analysis on these cells. As shown in Figure 5b , we did not observe any dramatic difference between the pCDNA3 control and hG9a-expressing cells after doxorubicin. The only significant difference specific for hG9a-expressing cells was the high level of cell in sub-G1 phase, which is indicative of cell death (Figure 5c , compare 24 vs 17.8% and 16% for hG9a, pCDNA3 and mG9a cells, respectively).
To confirm the role of hG9a in apoptosis we measured the level of cleaved poly[ADP-ribose]polymerase 1 (PARP) as a function of hG9a in H1299 cells transfected with p53-expressing plasmid and treated with doxorubicin ( Figure 5d ). Treatment of p53-expressing H1299 cells with doxorubicin caused significant cleavage of PARP, signifying the onset of apoptosis. Importantly, shRNA-mediated ablation of hG9a caused fourfold attenuation of the cleaved PAPR level (Figure 4d) , suggesting that the rate of apoptosis depends on hG9a. Furthermore, we were able to confirm these results in H460 (p53 + ) cells whereby hG9a but not the mouse one augmented cleavage of PARP1 after doxorubicin (Supplementary Figure S5) . Collectively, these results indicate that hG9a is a critical regulator of p53-dependent cell death.
Correlation between p53 and hG9a expression is associated with better survival To provide the biological significance to our observations on positive effect of hG9a on p53, we analysed the clinical data on whole-genome expression for correlations between co-expression of hG9a and p53 and the survival rates of cancer patients 43 ( Figure 6 ). Initially, we wanted to assess the importance of hG9a as a prognostic marker. Importantly, we found that high expression of hG9a positively correlated with better survival of stage I − II lung cancer patients (Figure 6a ). Next, we used GINT software, 44 which divides the expression data on the two genes of interest into two cohorts, one with no or strong negative correlation and the other one with strong positive correlation in their expression levels and links these to Kaplan − Meier survival probability estimates (Figure 6b) . Using different data sets we found that correlation in the expression between hG9a and p53 was associated with better survival of lung cancer patients (P = 0.002) (Figure 6b and Supplementary Figure S6 (P = 0.01). Furthermore, we also found that high expression of G9a (EHMT2) and p53 correlated with better survival of patients with colon cancer (P = 0.027) (Supplementary Figure S7) . These results highlight the biological significance of the hG9a-p53 association in several types of cancer. DISCUSSION p53 is one of the major tumour suppressors in vertebrates. The TP53 gene is conserved among different species, however the spectra of its post-translational modifications are quite different depending on the organism. 11, 12 For example, lysine methylation on K372 discovered for the human p53 protein, is absent in the mouse one. 45, 46 Further, sumoylation on K386 in the human p53 does not occur in its mouse paralog (Marouco et al. 12 and references therein). These data were in line with our observation that hG9a, unlike its mouse counterpart, cannot efficiently methylate p53 on K373 (Supplementary Figure S1) Our extensive studies, including luciferase assays, mRNA evaluation, and western blotting in several cell lines established human G9a as a p53 co-activator for at least a subset of genes, including the pro-apoptotic Puma. Several studies support the hypothesis that hG9a, depending on the chromatin context and protein-protein interactions, can either repress or activate transcription thus serving as a bivalent regulator of transcription. Importantly, transcriptional activation by G9a is exerted in a methyltransferase-independent manner. 33, 47 Accordingly, pharmacological inactivation of G9a with specific small molecules did not affect transcriptional activation of genes studied, which is in agreement with the results of our study (Figure 3b) . Then, how does G9a combine both activating and repressing functions? A possible explanation to this phenomenon relies on the fact that G9a is associated with multiple protein complexes (for example, Snail-G9a-DNMT1, REST-CDYL-G9a, G9a-p300-CARM1-GRIP1-MED), that play both positive and negative roles in transcription. 33, 48, 49 In our study, we detected CBP as a binding partner of hG9a (Figure 4) , which likely is recruited to the promoter of PUMA to acetylate histone H4 (Figure 4f ). Similar results were obtained for GR-dependent transcription where G9a recruited p300 to a subset of responsive genes. 40 Another study has shown that hG9a up-regulated transcription of the p21 gene upon DNA damage via interaction with another HAT, PCAF. 50 Collectively, these reports suggest that G9a mediates its activation functions via recruitment of HATs in the methylation-independent fashion.
Another important question that remains to be answered is why the human and mouse orthologs of G9a have diametrically opposed effects on p53? We speculate that such a drastic difference is mediated by structural differences in these proteins. The human G9a (EHMT2) gene is present in cells as hG9a(L) and hG9a(S) isoforms. The longest one resembles more the structure of the mG9a protein, which is the product of NG36-G9a transcript (Figure 1c) . 32 Previous studies have revealed differences in the sub-cellular distribution of the NG36-G9a and G9a proteins. The NG36-G9a is mostly located in the nucleus, whereas G9a localizes both to the cytoplasm and nucleus. 37 In fact, we also detected small amounts of hG9a in the cytoplasm (Figure 4d) . Additionally, the amino-terminus of mG9a contains eight GlycineArginine (G-R) repeats. The G-R repeats function as NLS and are found in proteins involved in gene expression, RNA splicing and translation. 51 However, in our case, mG9a blunted transcription by attenuating p53 binding to the promoters of its target genes via methylation on K373 (Supplementary Figure S3) . In conclusion, the question of why the human and mouse G9a proteins behave so differently towards p53 requires additional investigation.
Recently, Huang et al 23 has reported that allegedly human G9a protein inhibited p53 activity by methylating it on K373, which contradicts the results of our study. The most obvious explanation to this discrepancy is that Huang et al. may have used the mouse version of G9a, which is similar in size with the hG9a(L) form (Figure 1d ). Another reason behind this disagreement may be a result of using different cell lines. For example, Huang et al. 23 used MCF7 (Human Breast Adenocarcinoma) cells, 23 where our bioinformatics analysis failed to reveal the correlation between G9a expression and survival of cancer patients (data not shown).
It should be emphasized that the positive correlation between the p53-G9a expression and better survival of patients is tumorspecific. Our bioinformatics results, in addition to breast cancer, also failed to reveal any positive p53-G9a correlations for lymphoma, melanoma, and prostate cancers (data not shown). Despite the wealth of data on the oncogenic role of G9a, we found that at least in the initial stages of lung adenocarcinoma elevated expression of hG9a correlated with better survival rates (Figure 6a) , which fits the description of G9a as a bivalent regulator of transcription. Again, it should be noted that hG9a likely exerts its tumour-suppressive functions not only through gene activation of p53-dependent genes, but also via possible repression of other important regulators (Figure 7 ). It would be interesting to see whether hG9a also operates as an oncogene by cooperating with the Gain-of-Function mutant p53 and utilizes HMT activity to inhibit the tumour suppression programme in certain types of cancers. Unfortunately, the lack of appropriate bioinformatics data for cancers that displayed hG9a dependency did not allow us to perform such analysis. Finally, these findings should raise a risk alert in using G9a-specific pharmacological inhibitors as therapeutic tools to treat tumors with wild-type p53.
MATERIALS AND METHODS

Plasmid constructs
p53 plasmids and p21-, Bax-luciferase reporters used in this study were described previously. 18 pLKO-shCBP construct was purchased from Santa Cruz Biotechnology, Inc. (Heidelberg, Germany, sc-29952-SH). pCDNA3-mp53 construct was obtained from Dr P. Muller (MRC Toxicology Unit, UK). pGEX-SET domain plasmids were obtained from Dr O. Binda (Newcastle University, UK). pCDNA3-FLAG-hG9a(S), pCDNA3-FLAG-hG9a(L) were a gift from Dr Chiang (University of Texas Southwestern Medical Center, USA), pCDNA3-GLP was obtained from Dr Ueda (Kyoto University, Japan), pCDNA3-FLAG-mG9a and pCDNA3-FLAG-hGLP were obtained from Dr Stallcup (University of Southern California, USA), pCDNA3-Smyd2, pCDNA3-SMYD3, and pCDNA3-SetD2 were obtained from Dr Brown (University of Texas, USA), pLKO-shG9a (#5, #6, #8, #9, and #10) plasmids were a gift from Dr Seo (Chung-Ang University, South Korea).
Cell cultures and manipulations with cells
All cell lines used in this study (H1299, H460, HCT116, and E14) were obtained from ATCC, unless stated otherwise in the text. Human tumour cell lines were cultured in DMEM supplemented with 10% FBS (Thermo Fisher Scientific, Waltham, MA, USA) at 37°C with 5°CO 2 . Mouse E14 cells were grown in Knockout™ DMEM (Thermo Fisher Scientific) supplemented with 15% FBS (Thermo Fisher Scientific), 1 × glutamine/penicillin/ streptomycin (Thermo Fisher Scientific), 100 μM β-mercaptoethanol (Thermo Fisher Scientific), and mouse Leukemia Inhibitory Factor (Thermo Fisher Scientific). Transfections were carried out using Turbofect or Lipofectamin2000 reagents according to the manufacturer's protocols (Thermo Fisher Scientific, # R0531 and Invitrogen, respectively). To induce DNA damage cells were treated with 1 μM (if not stated otherwise in the text) of Doxorubicin hydrochloride (Sigma-Aldrich, Dorset, UK) for 16 h. BIX-01294 trihydrochloride hydrate (Enzo, #ALX-270-473-M002) was used to inhibit methyltransferase activity of G9a.
G9a and CBP Silencing
To down-regulate expression of G9a or CBP in H1299 or HCT116 cells, the indicated cells were transfected with shRNA against G9a (shRNA-hG9a #2) or shRNA against CBP (shRNA-CBP) using Turbofect. To increase the efficiency of shRNA-hG9a, a pool of plasmids expressing five different shRNAs against non-overlapping sequences of hG9a (#5, #6, #8, #9, and #10) was prepared by mixing equal amount of these plasmids before transfection. To examine the efficiency of knockdowns the corresponding cell lysates were prepared after 72 h post transfection and subsequently were analyzed by western blotting using the corresponding antibodies.
Luciferase Reporter Assay A total of 100 000 cells per well were seeded in 24-well plates 1 day before transfection. An amount of 1.0 μg of total plasmid DNA per well was used. 24 h after transfection, media was replaced by fresh growth media and part of samples was treated with 1.0 μM Doxorubicin. Twenty hours later, lysates were collected in lysis buffer and stored at − 80°C overnight. One quarter of 80 μl cell lysate was then analysed with luciferase assay kit (BioVision, UK) using Victor X3 Multilabel Plate Reader (Perkin Elmer, UK).
Protein − protein interactions and western blot analysis To study protein − protein interactions, cells were incubated in lysis buffer (PBS, 50 mM NaCl, 1% NP-40, 1 mM PMSF) for 20 min at 4°C and sonicated as above. An amount of 1 mg of protein extract was then cleared by centrifugation before subjecting to immunoprecipitation with 5 μg of the indicated antibody overnight at 4°C. Protein A/G agarose beads (Millipore, #16-157) were then added for 4 h with rotation at 4°C following western blotting analysis. Primary antibodies used in this study were: β-actin (Abcam, Cambridge, UK, #ab8227), G9a (Thermo Fisher Scientific, #MA5-14880), p53 (Calbiochem-Millipore, Watford, UK, #Op43), FLAG (Sigma-Aldrich, #F3165), p21 (Santa Cruz Biotechnology, #sc-53870), PUMA (Cell Signaling Technology, Beverly, MA USA, #4976), CBP (Santa Cruz Biotechnology, #sc-369).
Quantitative real-time PCR Expression of Puma, p21 and Bax genes was analysed by RT − PCR as described previously. 52 The following primers were used: (Puma) GACCTC AACGCACAGTACGA (FWD), CACCTAATTGGGCTCCATCT (REV); (p21) CACCG AGACACCACTGGAGG (FWD), GAGAAGATCAGCCGGCGTTT (REV). (GAPDH) GGGAAGGTGAAGGTCGGAGT (FWD), TTGAGGTCAATGAAGGGGTCA (REV).
ChIP Assays
ChIP assays were performed as described previously. 9 Antibodies used in ChIP were as follows: p53 (Calbiochem-Millipore #OP43), CBP (Santa Cruz Biotechnology #sc-369), Acetylated H4, Dimethylated H3K27, and Dimethylated H3K9 (Upstate Biotechnology, #06-599, #07-322, #07-212, respectively).
PCR was performed using the following primers: Puma: GCGAGA CTGTGGCCTTGTGT (FWD), CGTTCCAGGGTCCACAAAGT (REV). p21:GTGGCT CTGATTGGCTTTCTG (FWD), CTGAAAACAGGCAGCCCAAG (REV). Actin: TGGCTCAGCTTTTTGGATTC (FWD), CCGAGGATTGGAGAAGCAGT (REV).
Fluorescence-activated cell sorting analysis
Flow cytometry analysis was performed using Becton Dickinson FACSanto II FACSDiva 6.0 software (BD Biosciences, San Jose, CA, USA) as described in Lezina et al.
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Colony formation assay The colony formation assay was performed as described in Lezina et al. 53 Briefly, 500 cells of H460 (p53 +/+ ) cell line transfected with an empty vector or hG9a-or mG9a-expressing vectors were used in the assay. Twenty-four hours post transfection, cells were treated with 1.0 μM doxorubicin for 48 h to induce DNA damage. Cells were washed and incubated for additional 14 days at 37°C with 5% CO 2 to form colonies. Colonies were fixed in 80% methanol and stained with 0.1% crystal violet solution.
Western blotting
The primary antibodies used in this study were purchased from the following companies: CBP and p21 (Santa Cruz Biotechnology), FLAG-M2 (Sigma-Aldrich), G9a (Thermo Fisher Scientific), p53 (Calbiochem-Millipore), PARP and PUMA (Cell Signaling Technology, #9542S and #4976S, respectively), β-actin (Abcam #ab8227).
Co-Immunoprecipitation
Co-immunoprecipitations of FLAG-hG9a with p53 and CBP from transfected H1299 cells were carried out with anti-FLAG (Sigma-Aldrich) or normal mouse IgG antibody (Santa Cruz Biotechnology) overnight at 4°C. Following three washes with the binding buffer the Flag-G9a protein complex was eluted and analyzed by immunoblotting using FLAG-, CBP-, and p53-specific antibodies (as described above).
Indirect Immunofluorescence
Cultures of H1299 and H460 were grown on gelatin-coated 12-well plates and co-transfected with plasmids expressing FLAG-G9a and GFP-p53 using TransIT-2020 transfection reagent (Mirus Bio). Transfected cells were fixed with 4% paraformaldehyde for 20 min, permeabilized for 20 min with 0.2% Triton X-100 in PBS (pH 7.4) at room temperature. Cells were then incubated with primary antibodies (FLAG M2, 1:1000 dilution in 3% BSA/PBS (Sigma-Aldrich); anti-CBP 1:500 (Santa Cruz Biotechnology, #Sc-369)) for 4 h followed by secondary antibodies (Alexa Fluor 546 Donkey Anti-Mouse IgG, diluted at 1:500 in PBS (Life Technologies, Carlsbad, CA, USA)) for 1 h at room temperature. Following incubation the coverslips were rinsed with PBS and mounted with ProLong Diamond Figure 7 . G9a may differentially regulate p53 transcriptional activity. A model depicts both positive and negative effects of hG9a on p53 transcriptional activity. Human G9a acts as a coactivator for p53 through the recruitment of HATs including CBP and PCAF (left). However, G9a can also repress p53 transcriptional activity via recruiting the CDP/Cut, Gfi1, UHRF1, and WIZ complexes (right).
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